| This week's sponsor is Premier Research. | | | Discovering the Great Potential of Immuno-Oncology Drugs
Immuno-modulating agents have been around a long time, but for limited uses. New immuno-oncology pathways promise big advances against a wider range of cancers. Register now for our May 23 webinar. Premier Research. It's what we do. Best. |
Featured Story | Monday, May 15, 2017 The biotech industry is mourning the loss of one of the sector's founding fathers after the death of Genzyme founder Henri Termeer at the age of 71. Termeer was at the helm of Genzyme for nearly 30 years, joining the company in 1983 and rising quickly to the role of CEO before it was acquired by Sanofi in 2011 for more than $20 billion. |
|
|
| This week's sponsor is Medpace. | | | |
Top Stories | Monday, May 15, 2017 Biogen has paid $120 million upfront for Remedy Pharmaceuticals’ phase 3 stroke asset Cirara. The deal sees Biogen add a late-phase treatment for large hemispheric infarction to its pipeline in return for the upfront fee and undisclosed milestones and royalties. |
|
|
| Monday, May 15, 2017 Intellia Therapeutics has taken another step toward human trials of its gene editing technology after reporting data in a second animal species. |
|
|
| Monday, May 15, 2017 Genoa Pharmaceuticals has raised $62 million to take its lead candidate into the clinic. The Series A sets up new CEO Bruce Montgomery, M.D., to mount a clinical development program designed to establish the inhaled treatment for idiopathic pulmonary fibrosis as a rival to products from Boehringer Ingelheim and Roche. |
|
|
| Monday, May 15, 2017 Analysts have torn into AB Science over the clinical trial compliance failings identified by regulators in France. Oddo took the most extreme action by slashing its price target from €48 ($53) to €5, but even analysts with rosier assessments of AB’s situation fired off salvos at its management. |
|
|
| This week's sponsor is Cmed Research. | | | |
| | | Shares in Ionis Pharmaceuticals fell after a phase 3 readout revealed cases of thrombocytopenia. Release OrbiMed, Johnson & Johnson and Takeda Ventures led a $24 million Series A in microbiome startup BiomX. Statement Sarepta Therapeutics paid $22 million to Summit Therapeutics after the latter wrapped up enrollment in its phase 2 Duchenne muscular dystrophy trial. Release | |
|
Resources Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Rational Combinations 360° in Immuno-Oncology June 28-29, 2017 | New York, NY Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech Executive Breakfast- Tackling the Drug Price Problem: A Town Hall Debate June 21, 2017 | San Diego, CA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA MIXiii-BIOMED 2017 May 23-25, 2017 | Tel Aviv, Israel 8th Transparency and Aggregate Spend West May 23-24, 2017 | San Diego, CA Life Sciences Event of the Year! DIA 2017 Global Annual Meeting 2017 BIO International Convention: The Largest Global Biotech Partnering Event of the Year June 19-22 | San Diego, CA | 